header logo image


Page 13«..10..12131415..2030..»

Archive for the ‘Genetics’ Category

Dr. Krystof Bankiewicz–World-Renowned Neurosurgeon and Genetic Medicine Expert–Named President and Chief Executive Officer, Columbus Children’s…

Saturday, August 22nd, 2020

CHAPEL HILL, N.C., Aug. 20, 2020 /PRNewswire/ -- Columbus Children's Foundation (CCF), a national leading non-profit biotech organization helping children with ultra-rare genetic diseases, announced today that Krystof Bankiewicz, M.D., Ph.D., has been named president and chief executive officer. Bankiewicz will work closely with Executive Director Laura Hameed and CCF's esteemed board of trustee members, the CCF Cures Cabinet, and scientific advisors.

Bankiewicz, founder of multiple biotech companies and tenured professor in the Department of Neurosurgery at The Ohio State University College of Medicine, has been instrumental in the organization's success by developing and delivering multiple life-changing treatments as a CCF founding trustee.

According to CCF Chairman and Chief Science Officer R. Jude Samulski, "Dr. Bankiewicz has been quietly focused on bringing life-saving medicines to children that have shown tremendous therapeutic outcomes. He is a remarkable talent with a sincere focus on using his expertise to change the lives of children with significant unmet medical needs. We're thrilled to see someone with his mindset, expertise, and experience join us in this leadership role. Our organizational mission is aimed at ensuring no children are left behind when science can put cures in reach and Krystof will be a key player in effectuating that mission."

In this new role, Bankiewicz will orchestrate CCF's unique non-profit model for conducting translational research and developing pre-clinical and clinical novel therapeutic programs to advance treatments for children with ultra-rare, and often debilitating, genetic disorders.

"The significant impact Dr. Bankiewicz has had on the field of neuro-restorative medicine and gene therapy raises the Foundation's standing and its ability to accelerate curative solutions will help children around the globe," said Hameed. "Additionally, this innovative approach has the potential to change the market through developing cures while also ensuring equitable and affordable access for treatments. Access to cures without affordability creates tragic equity and access issues and I am thrilled that he has chosen to advance treatments using this innovative model. This approach brings out the best in science and humanity."

"In a world where economics do not add up for large biotech or pharmaceutical organizations to develop genetic medicine for smaller populations of children with ultra-rare conditions, by accelerating these programs in this manner, we can bring the focus needed to give these kids and their families a chance at life," said Bankiewicz. "Achieving the astounding results we are seeing in children who have already been treated and joining the Foundation to expand this impact is one of the most rewarding opportunities of my career. I look forward to doing my part to make a difference in children's lives and advance the ability to impact advancement in gene therapy more broadly."

Recognized in the medical community for groundbreaking accomplishments treating Parkinson's Disease and other conditions affecting the central nervous system, Dr. Bankiewicz pioneered delivery of gene therapeutics directly to the brain to treat neurological disorders. Among his many achievements as an industry and academic leader, he co-founded three companies, invented numerous medical patents and is author to more than 230 peer-reviewed research articles. Bankiewicz is a tenured professor of neurosurgery and Gilbert and Kathryn Mitchell Endowed Chair at The Ohio State University College of Medicine. Prior to that, he served as Kinetics Foundation chair in translational research and tenured professor in residence of neurological surgery and neurology at the University of California San Francisco.

Bankiewicz earned an M.D. from Jagiellonian University in Krakow, Poland, and a Ph.D., D.Sc., from the Institute of Neurology and Psychiatry in Warsaw. He also trained at National Institutes of Health in Bethesda, MD.

About Columbus Children's FoundationFounded in 2017, the Columbus Children's Foundation is a 501(c)3 non-profit in Chapel Hill, N.C. As one of the leading nonprofit biotech organizations, its mission is to help children diagnosed with ultra-rare genetic diseases. The Foundation has a global footprint with a sister Foundation located in Spain. Columbus Children's Foundation is focused on ultra-rare diseases that have lagged behind due to their small populations. Because the pharmaceutical industry tends to focus on more common illnesses with greater commercial potential, ultra-rare diseases are often overlooked, prompting the need for funding from outside the industry and a new model for advancement. The Columbus Children's Foundation also helps ensure that children with such disorders can participate in clinical trials or receive therapy if their families can't afford travel and related costs. For more information, visit the Columbus Children's Foundation or call (612) 437-8836.

Media Contact:Mark Rosenberg[emailprotected](919) 412-7378

SOURCE Columbus Children's Foundation

Read the original:
Dr. Krystof Bankiewicz--World-Renowned Neurosurgeon and Genetic Medicine Expert--Named President and Chief Executive Officer, Columbus Children's...

Read More...

Preimplantation Genetic Screening Market 2020 | Scope of Current and Future Industry 2026 – Scientect

Saturday, August 22nd, 2020

Global Marketers presents an updated and Latest Study on Preimplantation Genetic Screening Market 2020-2026. This report comprises a detailed study of the market covering its future predictions by the past year as a reference for the period between 2020 and 2026 as the forecast period. The report breakdowns major segments and highlights wider level geographies. The report bridges a perfect balance of both qualitative and quantitative information of the Preimplantation Genetic Screening Market. This report also offers an all-inclusive study of the future trends and developments of the market.

Get Pdf Sample Copy of this [emailprotected]:

https://www.globalmarketers.biz/report/healthcare/global-preimplantation-genetic-screening-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/143726#request_sample

Companies Profiled in this report includes:

Illumina, IncThermo Fisher Scientific Inc.Agilent Technologies, Inc.PerkinElmer, Inc.CooperSurgical, Inc.Beijing Genomics Institute

Preimplantation Genetic Screening Market forecast and review in five major regions: North America, Europe, Asia-Pacific (APAC), Middle East, and Africa (MEA), and South & Central America.

The key insights and evaluations presented in this Preimplantation Genetic Screening report are worth knowing for any market participant, helping them in ascertaining the superior dynamics and the future trajectories of the global Preimplantation Genetic Screening Market. The report explains the locale, economic situations with the item value, benefit, demand & supply with market development rate and figure.

By Product Type, Preimplantation Genetic Screening Market has been segmented into:

Next Generation Sequencing (NGS)Polymerase Chain Reaction (PCR)Fluorescent In-situ Hybridization (FISH)Comparative Genomic Hybridization (CGH)Single Nucleotide Polymorphism (SNP)

By Application, Preimplantation Genetic Screening Market has been segmented into:

Single Gene DisordersX-linked DisordersHLA TypingGender Identification

Inquire Before Buying:

https://www.globalmarketers.biz/report/healthcare/global-preimplantation-genetic-screening-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/143726#inquiry_before_buing

We, at Global Marketers, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small and with a team of highly experienced and dedicated analysts, we offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Key Questions Answered In The Report:

Major factors covered in the report:

Fundamentals of Table of Content:

Get Full [emailprotected]

https://www.globalmarketers.biz/report/healthcare/global-preimplantation-genetic-screening-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/143726#table_of_contents

Excerpt from:
Preimplantation Genetic Screening Market 2020 | Scope of Current and Future Industry 2026 - Scientect

Read More...

Biomedical research often ignores the diverse genetic ancestry of Black Americans – UPI News

Saturday, August 22nd, 2020

Aug. 20 (UPI) -- The genetic ancestry of Black Americans is exceptionally diverse, according to a new survey of residents in four U.S. cities.

The results, published this week in the journal PLOS One, call into question the use of skin color as a proxy for race in social science and biomedical research.

Historically, social scientists and biomedical researchers have treated Black people in the United States, including African American, African and Caribbean people, as a homogeneous group. According to the authors of the latest study, the practice is certain to erase important scientific nuances.

"This practice is not new and is reflective of age-old ideas and theories about human races," senior study author Rick Kittles, director of the Division of Health Equities at City of Hope Medical Center, a comprehensive cancer center near Los Angeles, told UPI in an email, adding that racial thinking presupposes that Black Americans are a homogeneous group.

"While current science does not support this, the racial thinking is still evident in study designs and conclusions drawn," he said.

In an effort to demonstrate the unique ancestral diversity that racial reductionism ignores, a team of physicians and scientists, led by Dede Teteh, postdoctoral researcher at City of Hope, analyzed the skin color, genetic ancestry and social attainment of 259 Black residents of Norman, Oklahoma; Cincinnati, Ohio; Harlem, New York; and Washington, DC.

"We focused on those factors because they all mediate how African Americans are seen and treated in the U.S.," Kittles said. "Skin color and genetic ancestry are how many people historically in the U.S. define race."

Their efforts revealed significant differences in ancestry, skin pigmentation and social attainment between the residents of the four cities.

Among the correlations revealed by the analysis, researchers found men with darker skin pigmentation were more likely to be married, while women were more likely to be wed if they had lighter skin color. Researchers also found residents with darker skin color and stronger West African ancestral roots were more likely to have earned graduate degrees and secured professional jobs than those with lighter pigmentation.

"There are still communities in the U.S. where skin color and genetic ancestry are strongly correlated with socio-economic variables and social attainment," Kittles said.

Researchers hope their work will motivate social scientists and biomedical researchers to account for the ancestral diversity of Black Americans as they design and execute studies.

"This research will help justify the need to take into account local history and experiences when one is studying African Americans," Kittles said. "African Americans are a macro-ethnic group with diverse genetic ancestries and local histories geographically here in the U.S."

In followup studies, researchers hope to expand their survey efforts to include larger populations of African Americans across the U.S.

"We'll also take into account variables such as racial identity and how that influences how African Americans see themselves and how they are seen by others in the health care system," Kittles said.

Read more here:
Biomedical research often ignores the diverse genetic ancestry of Black Americans - UPI News

Read More...

A genetic map hopes to trace rescued chimps back to their homes – Mongabay.com

Monday, August 17th, 2020

Experts estimate that nearly 2,000 chimpanzees may be lost to the wildlife trade each year. Once taken from the wild, young chimpanzees that survive the trauma of capture are sold as pets or for entertainment and can end up almost anywhere; theyve been intercepted by authorities in locations all over the globe.

Theyre confiscated in maybe Moscow, or San Francisco, or Hong Kong it can be anywhere and we dont know where they came from, says Peter Frandsen, a conservation genomics researcher at Copenhagen Zoo in Denmark.

Thats a problem when conservationists need to decide which countrys sanctuaries an animal should return to or where it could be safely reintroduced into the wild.

The answer may lie in the chimpanzees own genetic code. A global team of researchers is working to determine how chimpanzee genetics vary based on where the animals come from. By creating this genetic reference map, scientists hope to be able to determine the origins of confiscated chimpanzees as well as identify high-risk areas for wildlife trafficking.

Just a century ago, a million chimpanzees roamed the rainforests and grasslands of Africa. Now, fewer than 200,000 may be left in the wild, and conservationists fear that without widespread change these animals may go extinct in their natural habitats.

Pretty much all of the big conservation threats are facing chimpanzees right now, says Mimi Arandjelovic, a primatologist at the Max Planck Institute for Evolutionary Anthropology in Germany. Logging, mining, all of the extractive industries that are going on in equatorial Africa And then of course theres the huge threat of disease Theres the bushmeat trade, so people hunt and eat apes. And theres the primate pet trade.

Chimpanzees are currently listed as endangered by the IUCN (the western chimpanzee, one of four subspecies, is listed as critically endangered), and their numbers are still declining.

While chimpanzee conservation has many components, researchers say genetic studies are an increasingly important piece of the conservation puzzle.

One recently published study sheds new light on just how valuable genetic information could be in the conservation of this endangered species.

In this study, a group of researchers from Denmark, Spain, Russia and the U.K. analyzed nearly 60,000 ancestry-related genetic markers from captive-born and wild-born chimpanzees. In collaboration with dozens of zoos and sanctuaries across Europe and Africa, the researchers used hair samples to source DNA, a technique that is less invasive and stressful for animals than collecting blood.

Using the genetic data from wild-born chimpanzees whose birthplace was known, the researchers constructed a genetic reference map. They then compared this map with the DNA from chimpanzees who ended up in sanctuaries after being confiscated from illegal wildlife trafficking operations. In this way, researchers were able to estimate where the sanctuary chimpanzees had come from.

So just like popular DNA testing services for humans can tell us about our ancestry and origins, genetic information can reveal where chimpanzees come from.

Frandsen, one of the study authors, says learning where chimpanzees come from is important for many reasons.

For example, he says, genetic analysis provides essential information for captive-breeding programs. Even though chimpanzees may all look similar, there are actually four different accepted subspecies (and a fifth proposed subspecies), each with their own distinct range and unique genetic makeup. But there arent always records about where animals come from and which subspecies they are, which makes it difficult for captive-breeding programs to maintain the integrity of subspecies.

Frandsen says its important for captive-breeding programs to preserve these unique subspecies. Modern zoos are often referred to as Noahs Arks. You could call it a living museum sample, he says. So, we want to make sure that [zoo populations] resemble what you would find in the wild.

That way, he says, if a subspecies goes extinct in the wild, it wouldnt be lost altogether and eventually individuals of that subspecies could be reintroduced to the wild from these captive populations.

But genetic information may be even more valuable for combating animal trafficking.

Arandjelovic, who was not involved in the 2020 study by Frandsen and colleagues, says its unfortunately common for people to kill chimpanzee mothers for bushmeat and sell the babies as pets. Chimpanzees that are recovered from this wildlife trade can be candidates for reintroduction into the wild, so knowing where they came from is essential for deciding where they should be released.

Although Frandsen acknowledges that reintroduction can be challenging, especially as animals get older, he says its still very important. Theyre filling up in the sanctuaries, they dont have enough space and one of the main goals is to reintroduce as many as they can, he says. The sanctuary shouldnt be the endpoint for these chimpanzees if theres an opportunity to relocate them. Determining where an animal came from using genetic data may give it a better chance at a successful return to the wild.

Its possible that genetic data could even help prevent chimpanzee trafficking altogether. Identifying where chimpanzees in the illegal pet trade have come from could reveal poaching hotspots, thus allowing countries to appropriately target anti-poaching efforts. This is especially important in places where conservation funding may be limited.

But Frandsen says they dont yet have enough data to identify these high-risk areas. In this early proof-of-principle project, researchers analyzed just a few dozen animals that were rescued from the wildlife trade and ended up in sanctuaries. Frandsen says there are about 1,000 chimpanzees currently in African sanctuaries; the research team wants to expand their data collection to include these animals so that they can build a more accurate picture of poaching hotspots.

Future projects also include collecting more data from individuals born at known locations to build a more detailed genetic reference map, Frandsen says. The more detailed this map is, the more accurately researchers can determine where a trafficked animal has been taken from.

For some of the subspecies, we have pretty good data from the wild, Frandsen says. But for some of the other subspecies we are still data-deficient. So right now, the plan is to fill those knowledge gaps on the map.

Arandjelovic agrees that having accurate and detailed genetic reference maps is very important for determining the provenance of apes confiscated from the pet trade. She says the technique used in the present study analyzing thousands of different markers provides very detailed information about an individual. However, because of the cost and the specialized supplies needed to run this sort of analysis, it often cannot be done in the chimpanzees country of origin.

She says she wants to see if a reference map could be built using a simpler and cheaper technique that analyzes fewer locations in the genome. This technique would have the advantage of being more feasible to carry out in the countries where chimpanzees live. It would be great if we didnt have to export the samples, if we could do everything in-country, she says. That would be faster (we dont have to deal with permits), but we can also start capacity-building and having people in the country of origin do that work instead of sending it to Europe or North America. On the other hand, its not yet clear if this simpler technique would provide enough genetic information to create a useful reference map.

Frandsen and Arandjelovic agree that this is just the beginning for the application of genetic techniques to locate the origins of trafficked animals. The present study is a proof of concept, Frandsen says. So, theres a lot of work ahead to complete this project, but this is just for the chimpanzees, he says. Its also really a blueprint for other conservation projects. There are a ton of other taxa that this could be applied to.

Citation:

FEEDBACK: Use this form to send a message to the author of this post. If you want to post a public comment, you can do that at the bottom of the page.

Originally posted here:
A genetic map hopes to trace rescued chimps back to their homes - Mongabay.com

Read More...

Consistent associations between human genetic variation and the gut microbiome identified in 3 independent European cohorts – Gut Microbiota for…

Monday, August 17th, 2020

Many thousands of studies about gut microbiota and 16s RNA analysis are available to us nowadays. And while many results and interesting concepts emerge from those studies, a gold standard protocol for data analysis is not yet available. Moreover, the studies are carried out by different teams from different parts of the world, their designs are not the same, DNA extraction protocols differ, and 16s RNA region sequences vary between projects. As such, sample processing variables and the numerous environmental factors influencing an individuals gut microbiota mean association studies between the human genome and gut microbiota genome are less powerful.

Writing in Nature Microbiology, David A. Hughes and colleagues have created a new analytical pipeline that disentangles associations between human host genotype and gut microbiome variation in 3 distinct cohorts, paving the way for causal inference analyses in the field.

Researchers harmonized the analytical pipeline across three independent cohorts: the Flemish Gut Flora Project (n = 2,223) and two German cohorts (Food-Chain Plus, n=950; and PopGen, n= 717).

Using fecal 16s RNA gene sequencing, the researchers first estimated the proportion of gut microbiome variation explained by genetic variation (heritability) between individuals. In total, they identified 13 genera that were heritable. Eight were from the phylum Firmicutes, five of which were from the family Lachnospiraceae and two from Ruminococcaceae.

Dorea and Anaerostipes genera, which are short-chain fatty acid producers, along with Hespellia were three of the most heritable bacteria.

During a second stage, the researchers identified associations between bacteria species and human genes, encountering two strong associations:

The two strong associations were followed by the discovery of 11 associations showing low heterogeneity. Among those 11 associations, they found a relationship between the butyrate-producing genus Butyricicoccus and the SLC5A11 gene, which is a sodium-dependent myo-inositol glucose cotransporter that is highly expressed in the brain and intestine. The findings are in agreement with previous studies suggesting that butyrate-producing bacteria are associated with blood glucose and appetite regulation.

Another association was identified between Veillonella and rs117338748. This gene is involved in regulating low-density lipoproteins (LDLs) and transporting high-density lipoproteins (HDLs). The researchers observed that the presence of Veillonella was associated with a drop in LDL-cholesterol.

Using a Mendelian randomization model, the researchers estimated relationships between 5 microbial pathways and 7 outcomes (diseases). For instance, Bifidobacterium was associated with body composition. However, in the absence of clear microbiome-driven effects, any interpretation requires caution. In other words, it could be the causeless Bifidobacterium means the individual has a higher body mass index (BMI)or the consequencean individual with a higher BMI will present less Bifidobacterium in their gut.

In conclusion, this in-depth study on human genome-gut microbiome associations in 3 distinct cohorts generated a growing catalogue of genetic associations and showed better associations between the hosts genetics and its gut microbiota. Next steps should look at understanding the causation factors for a better understanding of gut microbiota function and association with outcomes.

Reference:

Hughes DA, Bacigalupe R, Wang J, et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat Microbiol. 2020. doi: 10.1038/s41564-020-0743-8.

View original post here:
Consistent associations between human genetic variation and the gut microbiome identified in 3 independent European cohorts - Gut Microbiota for...

Read More...

Why SARS disappeared in 2003 while the coronavirus keeps on spreading – Genetic Literacy Project

Monday, August 17th, 2020

The unusual cases of pneumonia began to appear in midwinter, in China. The cause, researchers would later learn, was a coronavirus new to science. By March, the infection began to spread to other Asian countries and overseas. People were dying, and the World Health Organization issued a global health alert.

But this was 2003, not 2020, and the disease was SARS, not Covid-19. By June, the outbreak was almost gone, with just 8,098 confirmed infections and 774 deaths worldwide. No cases of SARS have been reported since 2004.

Contrast that with the closely related coronavirus that causes Covid-19 today:more than 13,600,000 confirmed cases as of July 16, and more than 585,000 deaths.

Why did SARS go away while todays coronavirus just keeps on spreading? Why, for that matter, did both these coronaviruses spill over into people at all, from their original bat hosts?

And just as vital as those questions is another: What happens next?

As we face the current pandemic, it will be important to understand how SARS-CoV-2, the virus that causes Covid-19, is likely to evolve in the months and years ahead. Its possible the virus could lose its lethal character and settle into an evolutionary dtente with humanity. It might end up as just another cold virus, as may have happened to another coronavirus in the past. But it could also remain a serious threat or perhaps even evolve to become more lethal. The outcome depends on the complex and sometimes subtle interplay of ecological and evolutionary forces that shape how viruses and their hosts respond to one another.

One thing you learn about evolution is never to generalize, says Edward Holmes, an evolutionary virologist at the University of Sydney, Australia, and author of an article onthe evolution of emerging virusesin theAnnual Review of Ecology, Evolution, and Systematics. It depends entirely on the biological nuance of the situation.

Many of the scariest viruses that have caused past or current epidemicsoriginated in other animals and then jumped to people: HIV from other primates, influenza from birds and pigs, and Ebola probably from bats. So, too, for coronaviruses: The ones behind SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome) and Covid-19 all probably originatePostd inbatsand arrived in people via another, stepping-stone species, likely palm civets, camels and possibly pangolins, respectively.

But making the jump from one species to another isnt easy, because successful viruses have to be tightly adapted to their hosts. To get into a host cell, a molecule on the viruss surface has to match a receptor on the outside of the cell, like a key fitting into a lock. Once inside the cell, the virus has to evade the cells immune defenses and then commandeer the appropriate parts of the hosts biochemistry to churn out new viruses. Any or all of these factors are likely to differ from one host species to another, so viruses will need to change genetically that is, evolve in order to set up shop in a new animal.

Host switching actually involves two steps, though these can overlap. First, the virus has to be able to invade the new hosts cells: Thats a minimum requirement for making the host sick. But to become capable of causing epidemics, the virus also has to become infectious that is, transmissible between individuals in its new host. Thats what elevates a virus from an occasional nuisance to one capable of causing widespread harm.

SARS-CoV-2 shows these two stages clearly. Compared with the virus in bats, both the virus that infects people and a close relative in pangolins carry a mutation that changes the shape of the surface spike protein. The alteration is right at the spot that binds to host cell receptors to let the virus in. This suggests that the mutation first arose either in pangolins or an as yet unidentified species and happened to allow the virus to jump over to people, too.

But SARS-CoV-2 carries other changes in the spike protein that appear to have arisen after it jumped to people, since they dont occur in the bat or pangolin viruses. One isin a region called the polybasic cleavage site, which is known to make other coronaviruses and flu viruses more infectious. Another appears to make the spike protein less fragile, and in lab experiments with cell cultures, itmakes the virus more infectious. The mutation has become more common as the Covid-19 pandemic goes on, which suggests but does not prove that it makes the virus more infectious in the real world, too. (Fortunately, though it may increase spread, it doesnt seem to make people sicker.)

This evolutionary two-step first spillover, then adaptation to the new host is probably characteristic of most viruses as they shift hosts, says Daniel Streicker, a viral ecologist at the University of Glasgow. If so, emerging viruses probably pass through a silent period immediately after a host shift, in which the virus barely scrapes by, teetering on the brink of extinction until it acquires the mutations needed for an epidemic to bloom.

Streicker sees this in studies of rabies in bats which is a good model for studying the evolution of emerging viruses, he says, since the rabies virus has jumped between different bat species many times. He and his colleagues looked at decades worth of genetic sequence data for rabies viruses that had undergone such host shifts. Since larger populations contain more genetic variants than smaller populations do, measuring genetic diversity in their samples enabled the scientists to estimate how widespread the virus was at any given time.

The team found that almost none of the 13 viral strains they studied took off immediately after switching to a new bat species. Instead, the viruseseked out a marginal existence for years to decades before they acquiredthe mutations of as yet unknown function that allowed them to burst out to epidemic levels. Not surprisingly, the viruses that emerged the fastest were those that needed the fewest genetic changes to blossom.

SARS-CoV-2 probably passed through a similar tenuous phase before it acquired the key adaptations that allowed it to flourish, perhaps the mutation to the polybasic cleavage site, perhaps others not yet identified. In any case, says Colin Parrish, a virologist at Cornell University who studies host shifts, by the time the first person in Wuhan had been identified with coronavirus, it had probably been in people for a while.

It was our bad luck that SARS-CoV-2 adapted successfully. Many viruses that spill over to humans never do. About 220 to 250 viruses are known to infect people, but only about half are transmissible many only weakly from one person to another, says Jemma Geoghegan, an evolutionary virologist at the University of Otago, New Zealand. The rest are dead-end infections. Half is a generous estimate, she adds, since many other spillover events probably fizzle out before they can even be counted.

SARS-CoV-2, of course, is well past the teetering stage. The big question now is: What happens next? One popular theory, endorsed by some experts, is that viruses often start off harming their hosts, but evolve toward a more benign coexistence. After all, many of the viruses we know of that trigger severe problems in a new host species cause mild or no disease in the host they originally came from. And from the viruss perspective, this theory asserts, hosts that are less sick are more likely to be moving around, meeting others and spreading the infection onward.

I believe that viruses tend to become less pathogenic, says Burtram Fielding, a coronavirologist at the University of the Western Cape, South Africa. The ultimate aim of a pathogen is to reproduce, to make more of itself. Any pathogen that kills the host too fast will not give itself enough time to reproduce. If SARS-CoV-2 can spread faster and further by killing or severely harming fewer of the people it infects, we might expect that over time, it will become less harmful or, as virologists term it, less virulent.

This kind of evolutionary gentling may be exactly what happened more than a century ago to one of the other human coronaviruses, known as OC43, Fielding suggests. Today, OC43 is one of four coronaviruses that account for up to a third of cases of the common cold (and perhaps occasionally more severe illness). But Fielding and a few others think it could also have been the virus behind a worldwide pandemic, usually ascribed to influenza, that began in 1890 and killed more than a million people worldwide, including Queen Victorias grandson and heir.

Scientists cant prove that, because no virus samples survive from that pandemic, but some circumstantial evidence makes the case plausible, Fielding says. For one thing, people who were infected in the 1890 pandemic apparently experiencednervous-system symptomswe now see as more typical of coronaviruses than of influenza. And when Belgian researchers sequenced OC43s genome in 2005 and compared it to other known coronaviruses, they concluded that it likely originated as a cattle virus and may havejumped to people right around 1890. They speculated that it may have caused the 1890 pandemic and then settled down to a less nasty coexistence as an ordinary cold virus.

Other evolutionary biologists disagree. The pandemic certainly faded as more people became immune, but theres no solid evidence that OC43 itself evolved from highly virulent to mostly benign over the last century, they say. Even if it did, that does not mean SARS-CoV-2 will follow the same trajectory. You cant just say its going to become nicer, that somehow a well-adapted pathogen doesnt harm its host. Modern evolutionary biology, and a lot of data, shows that doesnt have to be true. It can get nicer, and it can get nastier, says Andrew Read, an evolutionary microbiologist at Penn State University. (Holmes is blunter: Trying to predict virulence evolution is a mugs game, he says.)

To understand why its so hard to predict changes in virulence, Read says its important to recognize the difference between virulence that is, how sick a virus makes its host and its transmissibility, or how easily it passes from one host individual to another. Evolution always favors increased transmissibility, because viruses that spread more easily are evolutionarily fitter that is, they leave more descendants. But transmissibility and virulence arent linked in any dependable way, Read says. Some germs do just fine even if they make you very sick. The bacteria that cause cholera spread through diarrhea, so severe disease is good for them. Malaria and yellow fever, which are transmitted by mosquitos, can spread just fine even from a person at deaths door.

Respiratory viruses, like influenza and the human coronaviruses, need hosts that move around enough to breathe on one another, so extremely high virulence might be detrimental in some cases. But theres no obvious evolutionary advantage for SARS-CoV-2 to reduce its virulence, because it pays little price for occasionally killing people: It spreads readily from infected people who are not yet feeling sick, and even from those who may never show symptoms of illness. To be honest, the novel coronavirus is pretty fit already, Geoghegan says.

Nor are there many documented instances of viruses whose virulence has abated over time. The rare, classic example is the myxoma virus, which was deliberately introduced to Australia in the 1950s from South America to control invasive European rabbits. Within a few decades, the virusevolved to reduce its virulence, albeit only down to 70 to 95 percent lethality from a whopping 99.8 percent. (It has since ticked up again.)

But myxoma stands nearly alone, Parrish says. For instance, he notes, there is no evidence that recent human pathogens such as Ebola, Zika or chikungunya viruses have shown any signs of becoming less pathogenic in the relatively short time since jumping to humans.

The faded nightmares of our past pandemics that terrorized, then receded, such as SARS in 2003 and flu in 1918-20 and again in 1957, 1968 and 2009 went away not because the viruses evolved to cause milder disease, but for other reasons. In the case of SARS, the virus made people sick enough that health workers were able to contain the disease before it got out of hand. People who got SARS got very sick, very fast and were easily identified, easily tracked and readily quarantined and their contacts were also readily identified and quarantined, says Mark Cameron, an immunologist at Case Western Reserve University in Cleveland, who worked in a Toronto hospital during the height of the SARS outbreak there. That was never going to be as easy to do for Covid-19 because people who dont show symptoms can spread the virus.

Flu pandemics, meanwhile, have tended to recede for another reason, one that offers more hope in our present moment: Enough of the population eventually becomes immune to slow the virus down. The H1N1 influenza virus that caused the 1918 pandemic continued as the main influenza virus until the 1950s, and its descendants still circulate in the human population. What made the virus such a threat in 1918-20 is that it was novel and people had little immunity. Once much of the population had been exposed to the virus and had developed immunity,the pandemic waned, although the virus persisted at a lower level of infections as it does to this day. It appears less lethal now largely because older people, who are at greatest risk of dying from influenza, have usually encountered H1N1 influenza or something like it at some point in their lives and retain some degree of immunity, Read says.

With the new coronavirus, Parrish says, were sort of in that 1918 period where the virus is spreading fast in a naive population. But that will change as more people either catch Covid-19 or are vaccinated (if and when that becomes possible) and develop some level of immunity. Theres no question that once the population is largely immune, the virus will die down, Parrish says.

The question is how long that immunity will last: for a lifetime, like smallpox, or just a few years, like flu? In part, that will depend on whether the vaccine induces a permanent antibody response or just a temporary one. But it also depends on whether the virus can change to evade the antibodies generated by the vaccine. Although coronaviruses dont accumulate mutations as fast as flu viruses, they do still change. And at least one, which causes bronchitis in chickens, has evolved new variants that arent covered by previous vaccines. But at this point, no one knows what to expect from SARS-CoV-2.

There is, at least, one encouraging aspect to all this. Even if we cant predict how the virus will evolve or how it will respond to the coming vaccine, there is something all of us can do to reduce the risk of the virus evolving in dangerous ways. And it doesnt involve any complicated new behaviors. Viruses can only evolve if theyre replicating and transmitting, Streicker says. Anything that reduces the replication of a virus will in consequence reduce the amount of evolution that happens. In other words, we can do our part to slow down the evolution of the Covid-19 virus by behaving exactly as weve been told to already to avoid catching it: Minimize contact with others, wash your hands and wear a mask.

Bob Holmes is a science writer in Edmonton, Canada, who hopes not to contribute to the further evolution of SARS-CoV-2. Find him at his website.

A version of this article was originally published at Knowable Magazine and has been republished here with permission. Sign up for their newsletter here. Knowable can be found on Twitter @KnowableMag

Original post:
Why SARS disappeared in 2003 while the coronavirus keeps on spreading - Genetic Literacy Project

Read More...

Genetic Variants and the Biology of Stillbirth – Technology Networks

Friday, August 14th, 2020

Columbia researchers have uncovered an array of new genes that cause stillbirth, significantly increasing the understanding of the condition's genetic foundations. The findings suggest that genetic analysis could be used to counsel parents who have previously experienced stillbirth and to unlock new human biology.

Using both standard and advanced analysis techniques, the team led by David Goldstein, PhD, and Ronald Wapner, MD, of Columbia University Vagelos College of Physicians and Surgeons (VP&S) identified the likely genetic cause of stillbirth in about one of every 10 cases studied.

"This study shows that careful genetic analyses can often identify the precise genetic causes of stillbirth and demonstrates the importance of diagnostic sequencing in all cases of unexplained stillbirth," says Goldstein, director of the Institute for Genomic Medicine at Columbia University Irving Medical Center. "Of equal importance, the work highlights how little we currently understand about the biology of stillbirth and the role that genomic analysis can play in helping us understand it."

The study was published online today in the New England Journal of Medicine by the Columbia team. Kate Stanley, MS, a research associate in the Goldstein lab, and Jessica Giordano, MS, a research genetic counselor in the reproductive genetics division of the Department of Obstetrics & Gynecology at VP&S, were co-first authors of the study.Presumed Genetic Underpinning, but Few Studies

Stillbirth (the in utero death of a fetus after 20 weeks' gestation) occurs in approximately one in 100 pregnancies and is about 10 times more common than sudden infant death syndrome.

But in the majority of cases, the cause of stillbirth is unknown. Some have been linked to maternal medical conditions such as infection and preeclampsia; 10% to 20% are attributed to large and easily detectable chromosomal abnormalities. Only a few genes have been implicated.

"Unlike postnatal childhood conditions that are presumed to be strongly genetic, stillbirth had yet to be systematically analyzed with modern genome sequencing approaches," says Goldstein.

"All too often, we have no explanation to give parents who experience a stillbirth," says Wapner, professor of obstetrics & gynecology. "Not only are they devastated, they're often left to wonder if it's something they did wrong or if it might happen again."

Genomic Sequencing Plus New Bioinformatic Analyses Find Hidden Genetic Causes

Genomic sequencing has been particularly useful in diagnosing otherwise unexplained childhood disorders and fetal structural defects, and the Columbia team used it for the first time to search for genetic variants that cause stillbirth.

The researchers sequenced all protein-encoding genes--where most known disease-causing genetic variants occur--from 246 stillborn fetuses and deployed new statistical analyses to identify the genetic mutations that caused the death of the fetus.

The combination of traditional sequencing and new analytical techniques revealed small changes in 13 genes that caused fetal death; six of the genes had not been previously linked to stillbirth.

"Although these are small changes in only a single site in the genome, they are, in effect, genomic sledgehammers that either dramatically change or knock out essential genes and appear responsible on their own for fetal demise," Goldstein says.

The small genetic changes explained 8.5% of the stillbirths in the study. When combined with a previous analysis of larger genomic alterations in this group, the researchers determined that 18% of the stillbirths had a known genetic cause.

The analysis also showed a critical difference compared with the study of postnatal genetic conditions.

"Interestingly, some of the changes we found in genes known to cause postnatal diseases and conditions appeared to have more profound effects than the mutations linked to postnatal disease," Goldstein adds.

Clinical Implications

Currently, the analyses required to find causal genetic causes of a stillbirth can be conducted in only a few academic medical centers.

But eventually the findings from this study--and future studies--will help physicians counsel parents and guide clinical care.

"To a woman who's just had a stillbirth, specific knowledge about the cause is critical," Wapner says. "They often blame themselves and some decide not to have any more children."

If the stillbirth can be attributed to a genetic mutation that has only occurred in the fetus, not in the parents, the same problem is unlikely to occur in future pregnancies.

"That knowledge would change the way we would provide care," Wapner says, "and facilitate closure and bereavement for families."

Unlocking New Human BiologyMost genetic diagnostic studies focus on genes already known to cause disease. Because stillbirth has been understudied, however, the team wanted to test whether genetic changes in genes not currently linked to disease contribute to stillbirth.

For this assessment, the researchers used a bioinformatic tool pioneered by the Goldstein lab that focuses on genes that are under the strongest natural selection in the human population--known as "intolerant" genes. The lab team showed that at least 5% of stillbirths are likely explained by mutations in intolerant genes that are not currently linked to any known human disease.

"These novel disease genes appear to be critical for early human development, and the only way to discover them is through the analysis of fetuses that do not develop," Goldstein says.

"We're opening up new frontiers in biology and the more we understand about basic human development, the more we can potentially intervene."

Reference: Stanley et al. (2020).Causal Genetic Variants in Stillbirth. The New England Journal of Medicine.DOI: 10.1056/NEJMoa1908753.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
Genetic Variants and the Biology of Stillbirth - Technology Networks

Read More...

Evaluating the Role of Genetics in Pediatric Suicidal Ideation and Aggression – Psychiatry Advisor

Friday, August 14th, 2020

Genetic variation combined with elevated aggression scores may predict childhood suicidal thoughts, while suicidal thoughts in childhood may point to young adult depression, according to data published in the Journal of Affective Disorders.

Researchers at the University of Pennsylvania wanted to determine if suicidal ideation in childhood was associated with genes indicative of suicidal ideation in adults. They also wanted to determine if aggression played a role in childhood suicidal thoughts.

A psychiatric disorder is present in more than 90% of adult suicides, according to the investigators, and aggression is associated with increased suicidal behaviors in both children and adults. Uncovering the role of childhood suicidal behavior on the development of psychiatric disorders later in life, as well as the influence of aggression, could help with suicide prevention efforts.

A total of 478 participants aged 8 through 18 years enrolled in the study and received ongoing assessment until age 19. Using multiple behavior assessment tools, researchers found that 25.9% of participants reported suicidal thoughts during 1 or more visits. These thoughts occurred for the first time at a median age of 13 years (mean age, 12.72.9 years; range, 8-18 years). Of the 17 children that attempted suicide, 10 reported aggression. Results of a Cox Survival analysis demonstrated a significant association between childhood aggression and suicide attempts.

To determine the role of genetics in the onset of suicidal thoughts, investigators tested specific haplotypes within ANKK1-DRD2 and HTR2C as potential predictors of suicidal thoughts and behaviors. Structural equation model results demonstrated that 3 single nucleotide polymorphisms (SNPs) within the HTR2C gene, 1 SNP in the ANKK1 gene, and 2 haplotypes AAAC in the ANKK1-DRD2 complex and the CCC haplotype in the HTR2C gene were significantly associated with suicidal ideation in childhood.

Limitations of the study include the relatively small sample size and the use of assessments conducted between 1990 and 2010, which does not account for the rise in suicide rates over the past decade.

Using genetic sequencing, researchers found specific haplotypes within ANKK1-

DRD2 and HTR2C genes are associated with either risk or resilience to developing suicidal

thoughts in childhood, depending on the individuals genetic background. Determining overall levels of aggression further helps determine which children will develop suicidal thoughts.

These observations have the potential to provide a framework for precision medicine that utilizes both genetic variation and phenotypic markers for early intervention and treatment, the researchers concluded.

Reference

Hill SY, Jones BL, Haas GL. Suicidal ideation and aggression in childhood, genetic variation and young adult depression [published online July 24, 2020]. J Affect Disord. doi: 10.1016/j.jad.2020.07.049

Read more here:
Evaluating the Role of Genetics in Pediatric Suicidal Ideation and Aggression - Psychiatry Advisor

Read More...

Genetics survival game Niche comes to Switch on the 3rd September – Gamasutra

Friday, August 14th, 2020

[This unedited press release is made available courtesy of Gamasutra and its partnership with notable game PR-related resource GamesPress.]

14th August - Zurich, Switzerland - Indie team Stray Fawn Studio (Nimbatus) today announced that their genetic survival sim Niche will be coming to Nintendo Switch! It will release on the 3rd September and pre-orders with a 10% discount are available now. The initial Steam release was met with great player feedback and currently has over 2700 users reviews, ranking the game as very positive.

Niche is a colourful genetic survival game about selectively breeding and evolving an adorable species of creatures to keep them alive against all odds, such as hungry predators, climate change and sickness. Combining turn-based strategies with simulation and roguelike elements, the game provides tons of different approaches to survive in the harsh environment.

Stray Fawn Studios game designer Philomena Schwab always had a strong affinity for biology and even struggled for a time to decide whether she wanted to pursue that field or game design. As a result, she decided to create Niche, a game about population genetics with a mating system based on real gene science, featuring mutation, dominant/recessive/codominant heredity and much more.

With a genetics system based on real DNA, the PC version of the game is currently also free for teachers to use in classrooms and is used by over 300 biology teachers for their studies.

Nintendo Switch review codes are available via [emailprotected] for editorial outlets.

Game features:

About Stray Fawn Studio

Stray Fawn Studio is an indie team from Zurich, Switzerland led by Micha Stettler and Philomena Schwab, with a focus on procedural world generation and creative freedom of the player.

Their first game Niche was initially released on Steam in September 2016, and since then

Stray Fawn Studio has delivered two other games, Nimbatus and Retimed.

The studio is now working on the Switch release for Niche, and a super-duper special unannounced project.

Continue reading here:
Genetics survival game Niche comes to Switch on the 3rd September - Gamasutra

Read More...

New Generation Genetics Bulls Lead the Way Following the Genetic Evaluations in August – Hoard’s Dairyman

Friday, August 14th, 2020

The information below has been supplied by dairy marketers and other industry organizations. It has not been edited, verified or endorsed by Hoards Dairyman.

Following the release of the August 2020 genetic evaluations, bulls from New Generation Genetics proven and genomic bulls ranked at or near the top for Milk, Components, Type, Udder Composite, Mobility, Fertility, DPR, Productive Life, NM$, PPR, & Profit.

54BS557 BMG Lust GET LUCKY *TM continues to lead the way as the #1 proven bull for milk, fat, and protein. Get lucky is also the #1 Proven bull for PPR at 189. His milk is +2594, +58f and +57p.

54BS558 Hilltop Acres B DAREDEVIL ET *TM is the breeds type leader with daughters impressing on farms and in the show ring. He continues as the #1 proven type bull at +1.0 with an udder composite now at +1.16.

54BS564 Jo-Lane Dario HAMPTON ET *TM dominates in health traits, profit, and fertility. After completing his 1st crop he ranks #4 for productive life at +5.2 with a +1.7 DPR. He is the new #5 proven Net Merit bull at $327 and #5 SCR ranking at +1.5.

54BS561 Hilltop Acres BV JESSE ET *TM is a new graduate at +624 milk, +0.6 type, +0.71 UDC, +0.7 DPR, and positive SCR. He offers an impressive outcross pedigree, phenomenal udders, and great dairy strength.

54BS601 La Rainbow Sweet SALSA ETV *TM Is the #1 G-type bull at +1.1 type and +1425 milk. This Genomic Gem is a LUCKY CARL brother to SILVER, giving him an impressive pedigree to back his historic numbers.

54BS604 La Rainbow Sweet SPARK *NP is a new genomic polled bull at +750 milk, +0.8 type, and +1.18 UDC, earning him #1 genomic polled status in these three categories.

196BS55878 Portmann BS Bays JONMAR *TM is an exciting new offering from Swissgenetics. He is the #8 G-PPR bull at 182 and #5 genomic Net Merit bull at $466. He is also +1158 milk, +43 fat, +40 protein, +0.79 UDC, and +2.1 DPR.

We also offer the CHAMPIONS COLLECTION elite sire lineup including 54BS600 WINRITE, 54BS602 FIRST CHOICE, 54BS539 RICHARD, 54BS581 RASTA, 54BS568 FAST & FURIOUS, and 54BS548 WINNING FORMULA.

New Generation Genetics offers the most comprehensive Brown Swiss Sires portfolio in the U.S. For further information call 920-568-0554, visit our Facebook page http://www.facebook.com/newgenerationgenetics, email info@brownswiss.com or visit http://www.brownswiss.com.

See the article here:
New Generation Genetics Bulls Lead the Way Following the Genetic Evaluations in August - Hoard's Dairyman

Read More...

Baylor Genetics and Rice University Form COVID-19 Screening Partnership for the Fall Semester; Partnership Aims for ‘Moon-Shot’ 48-Hours-or-Less…

Friday, August 14th, 2020

Baylor Genetics and Rice University form partnership to create a first-of-its-kind solution for the university to resume in-person classes for the fall semester despite the COVID-19 pandemic

HOUSTON, Aug. 13, 2020 /PRNewswire/ --Baylor Genetics, a clinical diagnostics laboratory known for genetic testing and precision medicine, and Rice University, a private, comprehensive research university located in Houston, Texas, have partnered together to create a first-of-its-kind, total turnkey solution for the university to resume in-person classes for the fall semester despite the COVID-19 pandemic.

"For Baylor Genetics and Rice University, this partnership represents a moon-shot opportunity to benefit students, faculty, and staff," stated Kengo Takishima, President and Chief Executive Officer at Baylor Genetics. "It is imperative families have peace of mind as they send their children to college and we've set an aggressive goal of serving as a blueprint for other academic institutionsand, more broadly, society."

Many universities nationwide have been strongly impacted by the pandemic and have announced changes to the fall semester. One of the major changes is universities going fully online for the semester. Fortunately, Rice has been able to overcome many challenges brought on by COVID-19 thanks to its partnership with Baylor Genetics.

"In terms of learning online, I found that it wasn't that intuitive and effective for my own learning style. In addition to that, it is my senior year and I wanted to get one last taste of the community that I have come to grow and love here," said Victor Nguyen, a senior at Rice University, in an interviewreleased by the university. "Being on campus again feels a little bit more of what we are used to, even though we live in a new reality. It's closer to normal so it's exactly what we were hoping for."

This partnership entails Baylor Genetics providing support for temperature checks, on-campus sample collection and transport logistics, processing of samples, and customized results reporting for individuals via email. Nearly 60,000 screening tests will be performed by Baylor Genetics with a turnaround time of 48 hours or less.

Story continues

In addition to large-scale surveillance testing, the partnership includes population management reporting. This custom reporting system delivers population data to assist policymakers at Rice with managing the campus community and by aiding in intelligent decision making.

"Testing by itself is not enough," said Kevin Kirby, Rice University's Vice President for Administration."What matters is how we use that information to act quickly to isolate, treat, contact trace, and quarantine those affected. A systematic approach is the best practice for creating an environment that will mitigate the spread of COVID-19."

In addition, data tracking will provide the university with specific trends and infection rates on buildings, facilities, and housing throughout the campus. This innovative approach is part of Rice's strategy to prevent cross-contamination and ensure the safety of its faculty, students, and staff. There are plans to extend the partnership with symptomatic testing in the near future.

"This opportunity is a chance to demonstrate that we can operate safely in such a difficult time," said Chad Shaw, Ph.D., Sr. Director of the Baylor Genetics Innovation Lab, Adjunct Professor of Statistics at Rice University, and Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine, "As a Houstonian and a member of both the Baylor and Rice faculty, I am excited by the opportunity to serve my community to find a thoughtful and creative way to overcome the COVID challenge. It takes commitment, grit, and a team effort."

The program began the week of Aug. 3 with college staff, graduate students, and orientation coordinators. For students, testing is broken down into three phases and will begin Aug. 15. There will be no charge to faculty, studentsor staff for the on-campus testing.

For members of the Rice community that are confirmed positive for the coronavirus (SARS-CoV-2), Rice will follow the Centers for Disease Control and Prevention contact-tracing protocols to identify others who have had significant contact with those tested positive.

Baylor Genetics' test for COVID-19 has one of the highest sensitivity (true positive rate) and specificity (true negative rate) rates for identifying active coronavirus infection. All precautions, policies, and guidelines have been put in place with one goal in mind continue education in the safest, most effective way possible.

Media Contact:Jamie LimEmail: pr@baylorgenetics.com

Related Images

on-campus-collection-site-at-rice.jpg On-campus collection site at Rice University

Related Links

COVID-19 Testing at Baylor Genetics

Return to Rice

View original content to download multimedia:http://www.prnewswire.com/news-releases/baylor-genetics-and-rice-university-form-covid-19-screening-partnership-for-the-fall-semester-partnership-aims-for-moon-shot-48-hours-or-less-turnaround-for-test-results-301111805.html

SOURCE Baylor Genetics

See original here:
Baylor Genetics and Rice University Form COVID-19 Screening Partnership for the Fall Semester; Partnership Aims for 'Moon-Shot' 48-Hours-or-Less...

Read More...

Scientists discover three new genetic variants linked to male breast cancer – The Institute of Cancer Research

Friday, August 14th, 2020

Image: Breast cancer cell. Credit: Anne Weston, Francis Crick Institute.

UK scientists have discovered three new genetic changes that increase the risk of breast cancer in men, in the worlds largest genetic study of the causes of male breast cancer to date.

Researchers, largely funded by Breast Cancer Now, identified three common variations in DNA that predispose men to developing breast cancer, bringing the total known number to five.

All three genetic variants are known to be linked to female breast cancer but scientists at The Institute of Cancer Research, London, and Queens University Belfast found the changes to have a greater effect on breast cancer risk in men than in women.

The study involved 1,380 men with breast cancer, primarily from the Breast Cancer Now Male Breast Cancer Study based at The Institute of Cancer Research (ICR). The team found that three genetic changes, called rs9371545, rs554219 and rs78540526, increased the risk of developing breast cancer in men by approximately 47, 45 and 61 per cent respectively.

The researchers then analysed over 170 SNPs known to affect risk in women, finding significant overlap in the genetic risk factors for the disease in men. The results suggest male and female breast cancer may have a very similar genetic basis a discovery which could in future lead to new preventive treatments for men and women.

The study also found that men at the highest genetic risk were almost four times more likely to develop breast cancer than those at lowest risk.

Breast Cancer Now described the discovery as a major step forward in our understanding of male breast cancer, calling for greater awareness of the disease in men and for research into the shared genetic causes of male breast cancer and the most common form in women (ER+), to develop risk-reducing drugs and other interventions to prevent more cases among those at increased risk.

The study was funded by Breast Cancer Now and Queens University Belfast, and is published in the Journal of the National Cancer Institute.

While breast cancer in men is very rare, around 370 men are diagnosed with the disease every year in the UK, and around 80 men lose their lives each year.

There are a number of different treatments for breast cancer in men depending on the features of the tumour, including surgery, hormone therapy, radiotherapy, chemotherapy and targeted drugs all of which were first developed to treat the disease in women.

More than 95 per cent of all breast cancers in men are oestrogen receptor (ER) positive compared to up to 80 per cent of cases in women meaning that they contain proteins called oestrogen receptors and can be stimulated to grow by the hormone.

Men with a strong family history of breast cancer among female relatives are known to be at greater risk, and around 10 per cent of male cases are caused by mutations in the BRCA2 gene. But the exact causes of the disease in men are not yet understood, and, for years, there has been considerable debate about whether male and female breast cancer are distinct from one another.

While mutations in genes such as BRCA2 can increase the risk of breast cancer by a great deal, these faults are relatively rare and major research has shown that single-letter changes to our DNA code (called Single Nucleotide Polymorphisms or SNPs) also influence cancer risk.

With up to 15 million places where SNPs can exist across our genome, these changes are relatively common.

In a major new genetic analysis pooling data from multiple studies worldwide, researchers led by Dr Nick Orr at the Breast Cancer Now Research Centre at The Institute of Cancer Research (ICR) and at Queens University Belfast compared the genomes of 1,380 men with breast cancer to 3,620 men without.

The scientists discovered three new SNPs that were significantly associated with an increased risk of breast cancer in men: one on chromosome 6 (rs9371545) and two on chromosome 11 (rs554219 and rs78540526).

The researchers then investigated the extent of the shared genetic causes of the disease in men and women by evaluating 172 regions in the genome linked to female breast cancer, for an association with male breast cancer.

The team found a strong correlation between the genetic risk factors of male and female breast cancer, with 20 per cent of SNPs that influence (increase or decrease) the risk of breast cancer in women also having an effect on male breast cancer risk.

The study also observed some important differences, with some SNPs carrying a greater increase in risk for women than for men or vice versa, and some SNPs also changing the risk in opposite directions for men than for women.

We've lost many vital research hours to the coronavirus crisis but the need for our work continues to grow. Please help uskick-startour research to make up for lost time in discovering smarter, kinder and more effective cancer treatments, andto ensure cancer patients don't get left behind.

Read more

Having identified this overlap, the researchers then investigated how well a DNA test (313 SNP risk score), which was designed to estimate breast cancer risk in women, worked for men.

They found there was nearly a four-fold increase in risk between men in the highest genetic risk category and those in the lowest (OR= 3.86), and that the distribution of cases across risk categories was similar to that observed in women.

The findings add to the major discovery in 2012 from the Breast Cancer Now Male Breast Cancer Studyby the same authors, that a single change in the genetic code of a gene called RAD51B can increase the risk of breast cancer in men by up to 50 per cent.

It is hoped that the discovery of new locations in the genome linked to male breast cancer could now enable scientists to identify the biological mechanisms that cause the disease to develop in men, and could ultimately lead to the development of new preventive drugs for those at high risk.

While further research would be needed, the authors also suggest the findings could in future help to develop more precise risk testing for men carrying BRCA2 mutations, enabling them to understand whether they are at additional or lower risk due to other genetic changes, which could help guide decisions around any risk-reducing steps.

Lead author Dr Nick Orr, who led the research at the ICR, and the Patrick G. Johnston Centre for Cancer Research at Queens University Belfast, said:

There has been much debate about whether breast cancers in women and men are distinct from one another. Our study has shown, for the first time, that the genetic factors influencing susceptibility to male breast cancer and the most common type of female breast cancer are much more alike than they are different.

Our findings suggest that the underlying biology that affects how breast cancer develops and grows are probably similar in men and women. This means that advances in prevention and treatment for the disease may be of benefit to all patients, irrespective of their gender.

Dr Simon Vincent, Director of Research, Services and Influencing at Breast Cancer Now, which funded the study, said:

This study, which shows more of a similarity between the genetic causes of the disease in men and women than previously thought, is a major step forward. Our knowledge of breast cancer in men is limited, because male breast cancer is rare which makes it difficult to collect enough tissue or blood samples to research and understand the disease. Research like this is critical to improving our understanding of the disease in men and we hope the Breast Cancer Now Male Breast Cancer Study will continue advancing our knowledge.

We now look forward to further research into the shared genetic causes of male breast cancer which could lead to developing risk reducing treatments and interventions to help prevent more cases among those at increased risk in the future.

The Breast Cancer Now Male Breast Cancer Study is the largest collection of DNA and tumour samples from men with breast cancer in the world, with over 1,000 men who have been diagnosed participating, as well as over 1,000 men without breast cancer. Based at the ICR, the study was established in 2008 to pinpoint the genetic, environmental and lifestyle causes of breast cancer in men.

Jo Tridgells husband John died in January 2017 after being diagnosed with breast cancer in November 2015. John took part in several research projects, including the National Male Breast Cancer Study led by the ICR. Commenting on the new research, Jo said:

When my husband John was going through treatment, it was always a question mark for me whether breast cancer in men warranted different drugs than that in women. This new study shows that the disease is genetically similar irrespective of your sex, so that feels like a real breakthrough knowing that treatment courses could be the same. Any research that helps us to understand how breast cancer risk can be monitored and the disease prevented in future is of vital importance to families like ours.

Read more here:
Scientists discover three new genetic variants linked to male breast cancer - The Institute of Cancer Research

Read More...

Experts develop genetic risk score to predict heart disease in South Asia – Express Healthcare

Friday, August 14th, 2020

Findings and methods developed can be used to screen large populations and high-risk individuals at a cost less than Rs 5000, according to the release

Findings of the first-ever research capturing the polygenic risk score for South Asia populations for coronary artery disease were recently published in the Journal of the American College of Cardiology (JACC).

Conducted by MedGenome Labs, in collaboration with researchers from Broad Institute of MIT and Harvard; Massachusetts General Hospital, Boston; Narayana Health, Bangalore; Eternal Hospital, Jaipur; Madras Medical Mission, Chennai; KMCH, Coimbatore and a few other institutes, the study on Indian population validates a novel CAD-PRS (coronary artery disease-genome-wide polygenic risk score) to precisely predict the risk of developing a coronary artery disease/myocardial infarction (MI) using a persons genetic makeup.

Knowing the polygenic risk is important to individuals with a family history of CAD, hypertension, diabetes, high cholesterol level, smoking habits, alcohol consumption, stressful lifestyle, as CAD results from a combination of these factors. A poor lifestyle and high polygenic risk could be a fatal combination and may result in early-onset CAD.

Such findings and methods developed can be used to screen large populations and high-risk individuals at a cost less than Rs 5000.

Looking at all the available scientific evidence and our study results we are convinced that there exists a good opportunity to combine both clinical and genetic risks (polygenicrisk score based) and significantly improve the primary prevention of coronary artery disease (CAD). We firmly believe that incorporatingvalidated genetic risk scores would help in better stratification of high-risk individuals if implemented at population level,said Dr Vedam Ramprasad, CEO, MedGenome Labs.

This unique study is based on the principle of Genome-wide Polygenic Risk Score (PRS) which usesa genome-wideanalysis of an individual to quantify the risk of developing heart disease.

It was conducted on the south Asian population in 1800 confirmed CAD cases and 1163 control samples from five centres across the country with a median age between 54 and 55 years. The findings of this study have helped develop a CAD PRS that integrates information from millions of sites of common DNA variation into a single metric that can be calculated from birth and validate a scalable polygenic score framework in India. This finding lays the scientific and operational foundation for clinical implementation not just for CAD but for other diseases.

CAD PRS is a powerful genetic predictor that can be used to identify individuals at increased risk for CAD. It provides a quantified risk score based on ones genetic makeup and predicts a patients risk for having an acute coronary event, such as a heart attack, before symptoms appear. CAD PRS is an important new risk factor to help physicians stratify high-risk patients and better guide treatment decisions and lifestyle interventions, said Dr Sekar Kathiresan, CEO, Verve Therapeutics and Professor of Medicine, Harvard Medical School, Cardiology Division, Massachusetts General Hospital.

According to a research paper published in theJournal of Genetics, the estimated prevalence of CAD disease in India is about 10.5 per cent of the population which extrapolates to a burden of about 32 million affected individuals. Over and above, the incidence of cardiac disorders has increased from 2 per cent to 10.5 per cent of the urban population in the past few years and early age of onset is a new countrywide trend.

South Asians no matter where they stay in India or any other country always have higher cases of CAD than Caucasians. Even if our body structure is much leaner, smaller and thus comparatively lower food consumed compared to Caucasians, we still end up with CAD. So, it can be considered that South Asians have some genetic issue that is causing high CAD cases and hence we need to identify these genetic factors so that we are able to manage the disease in our population, said Dr Ajit Mullasari, Director, Adult Cardiology, Madras Medical Mission.

The virtual press conference and announcement was also supported by several eminent cardiologists from across the country Dr Ramesh Seshadri, Dr Julius Punnen, Dr Varun Shetty, Dr Bagirath Raghuraman from Narayana Institute of Cardiac Science, Bangalore, Dr.Pradeep Narayan, RTIIS, Kolkata, Dr Rajendra N.S, Narayana Hospital, Mysore and Dr Rajeev Gupta, EHCC Jaipur.

Excerpt from:
Experts develop genetic risk score to predict heart disease in South Asia - Express Healthcare

Read More...

Insights on the Global Animal Genetics Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio – Business…

Friday, August 14th, 2020

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the animal genetics market and it is poised to grow by USD 1.79 billion during 2020-2024, progressing at a CAGR of 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Animal Genetics Inc., AquaGen AS, Aviagen Group, Coperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc., Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin, and Zoetis Inc. are some of the major market participants. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Animal Genetics Market 2020-2024: Segmentation

Animal Genetics Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40040

Animal Genetics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our animal genetics market report covers the following areas:

This study identifies the increase in consumption of animal-derived food products as one of the prime reasons driving the animal genetics market growth during the next few years.

Animal Genetics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the animal genetics market, including some of the vendors such as Animal Genetics Inc., AquaGen AS, Aviagen Group, Coperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc., Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin, and Zoetis Inc. Backed with competitive intelligence and benchmarking, our research reports on the animal genetics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Animal Genetics Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY SOLUTION

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View post:
Insights on the Global Animal Genetics Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio - Business...

Read More...

New study sheds light on genetic affinities of Gujjars and Ladakhis – Down To Earth Magazine

Friday, August 14th, 2020

The study is the first comprehensive attempt to determine the genetic relatedness of the Gujjars and Ladakhis to populations within India and elsewhere in the world

The Union Territories of Jammu and Kashmir (J&K) and Ladakh in North India, withtheir wide variety of landscape,are a congruence of several languages and cultural practices. The region is believed to have served as a corridor for ancient human migrations between the Indian subcontinent and North-East Asia, Eurasia and Africa.

The populations in the region offer a unique opportunity to investigate the past anthropological and demographic events which might have shaped the extant human population diversity. In a new study, scientists at the Department of Biotechnologys Centre for DNA Fingerprinting and Diagnostics (DBT-CDFD) have sought to decipher the genetic diversity encompassed by Gujjars from the Jammu region of J&K and the Ladakhi populations.

A previous study had found that the two communities Gujjars and Ladakhis exhibited lower genetic affinity towards other populations in their geographical proximity. To better understand the genetic diversity in these populations, a battery of DNA markers located on autosomes, Y-chromosome and the mitochondrial genome were employed.

The principal coordinate and cluster analysis based on autosomal DNA markers indicated Gujjars and Ladakhis were genetically distant to each other as well as to other reference populations of India, which was in concordance with Y-chromosomal analysis.

The genetic affinity of Gujjars in the Jammu region to Pashtuns in the Baghlans and Kunduz provinces of Afghanistan and Pashtuns and Sindhis in Pakistan indicated their past genetic relatedness and a common ancestry. On the other hand, Ladakhis were found to be genetically close to Chinese (Uighurs and Han) and Nepalese (Magar) populations, which might be due to their close geographic proximity.

Y-haplogroup (which represent a group of individuals who have inherited a common set of markers)-based studies suggested that the Gujjars are less diverse as compared to Ladakhis. The presence of many rare haplogroups in Ladakhis portrays rich accumulation of male-mediated contribution in the past.

The mitochondrial DNA analysis supported the findings that the Gujjars are less genetically diverse as compared to Ladakhis, which perhaps may be due to the endogamous cultural practices in this group (where they marry within a specific community or caste or group). The Y-chromosomal and mitochondrial analysis showed higher genetic differentiation among males than females indicating patrilocality among these populations.

The present study is the first comprehensive attempt to determine the genetic relatedness of the Gujjars and Ladakhis to populations within India and elsewhere in the world and would help in gaining deeper insights into genetic diversity and demographic settlement in this part of the world.

The researchers, Mugdha Singh, Anujit Sarkar, Devinder Kumar and Madhusudan R Nandineni, have published a paper in Scientific Reports titled `The genetic affinities of Gujjar and Ladakhi populations of India. (India Science Wire)

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Continued here:
New study sheds light on genetic affinities of Gujjars and Ladakhis - Down To Earth Magazine

Read More...

Genetic mutation may hold answers to controlled breathing – Newswise

Friday, August 14th, 2020

Newswise The protein Connexin 26 has been previously identified as being directly sensitive to Carbon dioxide and linked to conditions such as KIDS syndrome and deafness.

Thanks to a 686,956grant from the BBSRC, researchers from the School of Life Sciences at the University of Warwick will investigate the role of Connexin 26 (Cx26) in the control of breathing

They will highlight whether carriers of certain mutations of Cx26 are more likely to suffer from a reduced respiratory drive, and ability to regulate breathing

The relationship between the Cx26 gene and ability to regulate Carbon dioxide is to be explored by researchers from the School of Life Sciences, at the University of Warwick, thanks to a 686,956grant, from the BBSRC.

Professor Nicholas Dale, from the School of Life Sciences at the University of Warwick has previously identified that the protein Connexin 26 (Cx26) is directly sensitive to Carbon Dioxide (CO2).

Cx26 protein can have different mutations, which have previously been linked with KIDS syndrome, and deafness, this shows that both types of mutation can cause Cx26 to lose sensitivity to CO2.

Thanks to a 686,956grant from the BBSRC, researchers from the School of Life Sciences at the University of Warwick hope that their project, New tools for investigating connexin26 hemichannel function in physiological systems, may be able to directly identify a link between how Cx26 responds to CO2and its ability to control breathing. In the long term this could lead to understanding of how gene mutations interfere with this, and could help to develop new tests and treatments for breathing problems such as sleep apnoea.

Cx26 can respond to CO2in two different ways. This research aims to allow researchers to pin down which one of these two ways is involved in the control of breathing. To do this they will exploit how the Cx26 gene evolved from fish to man. Using the sequenced genome of Lungfish, researchers have previously researched Cx26 in the lungfish, which is closely related to the first existing species that crawled from water onto land and are air breathing. When studying the lungfish Cx26 protein researchers found that the lungfish Cx26 had only one way of responding to CO2, because the protein is slightly different, and has a long extension of 24 amino acids on one end of it.

Researchers plan to exploit this extension as a genetic tool, and hope that adding the extension of amino acids from lungfish Cx26 to human Cx26 will result in a subunit that can co-assemble with the native protein to remove one form of signalling. If this can be proven, researchers can look at breathing and see the extent to which one form of signalling contributes to breathing. If established it will lead to ways of treating the defects in the Cx26 molecule in humans carrying Cx26 mutations.

Professor Nicholas Dale, from the School of Life Sciences at the University of Warwick comments:

We hope that by the end of this four year project we can definitively establish how Cx26 controls breathing, and give new insight into how mutations of this key molecule could lead to altered control of breathing in humans.

If all goes well, in the long term it could provide new ways to diagnose breathing problems such as sleep apnoea, and introduce new clinical management strategies for Cx26 patients with mutations that affect CO2sensitivity to improve their quality of life.

View original post here:
Genetic mutation may hold answers to controlled breathing - Newswise

Read More...

Premier Medical Laboratory Services Named Among Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook – Business Wire

Friday, August 14th, 2020

GREENVILLE, S.C.--(BUSINESS WIRE)--Premier Medical Laboratory Services (PMLS) announces today that they have been named one of the Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook, a leading national healthcare publication. The designation, earned by the Greenville, SC laboratory, comes with recognition for their providing the most advanced diagnostic testing solutions with accuracy and efficiency through employing the latest in science and technology.

One of the reasons PMLS was selected by the publication is that they are a highly complex laboratory with various types of test offerings to address many medical diagnostic needs. From COVID-19 PCR tests, antibody testing, pharmacogenomics, advanced cardiovascular testing, and their womens health & wellness and diabetes panels, all of PMLS tests are performed under one roof with cutting-edge laboratory equipment, providing a quick turnaround of results for physicians and patients.

We are honored to be designated as a top genetic diagnostic company of 2020 by Healthcare Tech Outlook, said Kevin Murdock, Founder of Premier Medical Laboratory Services. Our team of scientists and laboratory personnel is continually focused on providing the most advanced solutions to diagnostic testing demands, and to helping physicians provide top-level care to their patients.

Along with titling PMLS a top genetic diagnostic company, Healthcare Tech Outlook noted that Premier Medical Laboratory Services MDDiabeticPro panel includes the revolutionary DIABETESpredict test, which is a first of its kind predictive genetic test for type 2 diabetes developed in collaboration with world leading doctors and scientists of Harvard and MIT. The DIABETESpredict test is expected to mark a new era in diabetes prevention and care through evaluating the risk of the disease onset by examining individual genetic profiles and is currently available to the US through PMLS.

Along with their MDDiabeticPro panel, the article also recognizes PMLS full respiratory pathogen panel and GI panel, as well as their cardiovascular panel MDHeartPro, which more accurately depicts a patients overall heart health than a standard lipid panel that is often used by other laboratories. All of these testing services are conducted at PMLSs 40,000 sqft COLA and CLIA regulated laboratory in Greenville, South Carolina alongside their recently added portfolio of COVID-19 related tests.

By employing the latest in laboratory equipment, added staff and a highly advanced laboratory information management system, OnGen, PMLS has been able to expand their testing capacity and add quality PCR and antibody testing for COVID-19 to their diagnostic testing services. Additionally, the article explores how PMLS has found solutions to overcome COVID-19 supply chain shortages in coordination with their sister company, CPT Medical, who makes their own viral transport media and specimen collection kits.

Healthcare Tech Outlook states, PMLS is a highly sophisticated and top of the line advanced diagnostics lab with robust diagnostic services.

To read the full article, please visit this link: https://bit.ly/2POMkYW.

For more information about Premier Medical Laboratory Services, please visit http://www.PreMedInc.com or call 1.877.335.2455.

ABOUT PREMIER MEDICAL LABORATORY

Premier Medical Laboratory Services (PMLS) is a CLIA and COLA regulated laboratory based in Greenville, South Carolina focused on providing clinically meaningful results to medical practitioners. Premier Medical Laboratory Services offers a variety of highly specialized tests including: the only Type II Diabetes molecular predisposition test available in the U.S., advanced cardiovascular testing, hereditary cancer screening, carrier screening, womens health panels, pharmacogenomics, serum allergy testing, blood wellness, Hepatitis C genotyping, respiratory pathogens, gastrointestinal pathogens, and more. In addition to its specialty programs, Premier Medical Laboratory offers a comprehensive testing menu of general chemistry, immunoassay, and hematology tests. The company also is proud to offer a patient friendly billing policy.

For more information, please visit http://www.PreMedInc.com or call 1.877.335.2455.

View original post here:
Premier Medical Laboratory Services Named Among Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook - Business Wire

Read More...

Genetic features and application value of next generation sequencing in the diagnosis of synchronous multifocal lung adenocarcinoma – DocWire News

Friday, August 14th, 2020

This article was originally published here

Oncol Lett. 2020 Sep;20(3):2829-2839. doi: 10.3892/ol.2020.11843. Epub 2020 Jul 9.

ABSTRACT

The present study aimed to elucidate the genetic features of multiple lung cancer (MLC) and identify effective molecular markers for diagnosis using next generation sequencing (NGS). The present data may also inform patient treatment and prognosis. A total of 35 lesions were obtained from 17 patients with MLC. Based on lesion histology and NGS, 13 cases of multiple primary lung cancer (MPLC) were identified and 4 cases were classified as intrapulmonary metastasis (IPM). All 4 patients with IPM exhibited an epidermal growth factor receptor (EGFR) mutation and synchronous mutation of at least one tumor suppressor gene. The frequency and percentage of EGFR mutations, accompanied with tumor suppressor genes, were significantly higher in patients with IPM compared with MPLC. Furthermore, a high EGFR-heterogeneity score and male sex were risk factors of IPM occurrence. There were significant differences in mean EGFR mutation abundance alone, mutations of tumor suppressor genes and mutations of EGFR combined with tumor suppressor genes between patients with adenocarcinoma (ADC) and adenocarcinoma in situ (AIS). In conclusion, histological characteristics combined with genetic alterations may be an effective method for the diagnosis of MPLC and IPM, and NGS may serve as a useful diagnostic tool. MLC exhibited unique molecular characteristics, including higher rates of EGFR mutations, EGFR driver mutations accompanied with tumor suppressor gene mutations and the absence of anaplastic lymphoma kinase mutations, which may help distinguish between patients with MPLC or IPM. The present study hypothesized that the mean frequency of EGFR mutations, mutations of tumor suppressor genes and mutations of both EGFR and tumor suppressor genes may serve an important role in the development of AIS to ADC. The results of the present study highlight the potential underlying mechanisms of lung ADC development, which may assist with future elucidation of effective treatments to prevent the progression of lung cancer.

PMID:32782601 | PMC:PMC7400153 | DOI:10.3892/ol.2020.11843

More here:
Genetic features and application value of next generation sequencing in the diagnosis of synchronous multifocal lung adenocarcinoma - DocWire News

Read More...

New genetic cause of an inherited neuropathy discovered | Penn Today – Penn Today

Friday, August 14th, 2020

Inherited mutations in a gene that keeps nerve cells intact was shown, for the first time, to be a driver of a neuropathy known as Charcot-Marie-Tooth (CMT) disease. This finding is detailed in a study led by researchers in the Perelman School of Medicine, which published inNeurologyGenetics, an official journal of the American Academy of Neurology.

The findings, thanks to siblings treated at Penn since the late 1980s, present a clearer picture of the diseases genetic underpinnings that could inform the development of gene therapies to correct it.

The mutations in the gene known as dystonin (DST) add to a growing list of malfunctions found to cause their type of CMT, known as CMT2, which is defined by the loss of the nerve fibers, or axons, in the peripheral nerve cells. The researchers also showed that these mutations affect two key protein isoforms, BPAG1-a2 and BPAG1-b2, that are involved in nerve fiber function. Mutations in other isoforms of the same protein were previously tied to a blistering skin disease.

There are more than 100 mutations found to be associated with CMT, with likely many more out there.Past studies from Penn researchers haveidentified some of these mutations by studying patients treated at Penn Medicine.

We are determined to fill in the blanks of this giant jigsaw puzzle, says senior authorSteven S. Scherer, a professor of neurology. This latest paper is but one of many examples of where breakthroughs have happened between patients and the doctors at Penn and the support of different organizations and institutions to bring it all together."

Read more at Penn Medicine News.

Continued here:
New genetic cause of an inherited neuropathy discovered | Penn Today - Penn Today

Read More...

Experts develop a breakthrough genetic risk score for Heart Disease in South Asia – ETHealthworld.com

Friday, August 14th, 2020

Bengaluru: MedGenome Lab has conducted a first-ever study on Indian population that validates a novel CAD-PRS (coronary artery disease-genome-wide polygenic risk score) to precisely predict the risk of developing a coronary artery disease/myocardial infarction (MI) using a persons genetic makeup.

MedGenome collaborated with researchers from Broad Institute of MIT and Harvard; Massachusetts General Hospital, Boston; Narayana Health, Bangalore; Eternal Hospital, Jaipur; Madras Medical Mission, Chennai; KMCH, Coimbatore and a few other institutes to conduct this first-ever research capturing the PRS of disease for South Asia populations and its findings are now published in the Journal of the American College of Cardiology (JACC).

Dr. Vedam Ramprasad, CEO, MedGenome Labs said Looking at all the available scientific evidence and our study results we are convinced that there exists a good opportunity to combine both clinical and genetic risks (polygenic risk score based) and significantly improve the primary prevention of coronary artery disease (CAD)."

The unique study is based on the principle of Genome-wide Polygenic Risk Score (PRS) which uses a genome-wide analysis of an individual to quantify the risk of developing heart disease.

It was conducted on the south Asian population in 1800 confirmed CAD cases and 1163 control samples from five centres across the country with a median age between 54 and 55 years.

The findings of this study have helped develop a CAD PRS that integrates information from millions of sites of common DNA variation into a single metric that can be calculated from birth and validate a scalable polygenic score framework in India.

This finding lays the scientific and operational foundation for clinical implementation not just for CAD but for other diseases. Such findings and methods developed can be used to screen large populations and high-risk individuals at a cost less than 5000 INR.

Knowingly, the polygenic risk is important to individuals with a family history of CAD, hypertension, diabetes, high cholesterol level, smoking habits, alcohol consumption, stressful lifestyle, as CAD results from a combination of these factors. A poor lifestyle and high polygenic risk could be a fatal combination and may result in early-onset CAD.

Go here to read the rest:
Experts develop a breakthrough genetic risk score for Heart Disease in South Asia - ETHealthworld.com

Read More...

Page 13«..10..12131415..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick